Amazon launches AI research tool to speed early-stage drug discovery | Reuters

Open original

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

  • AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
  • In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
  • Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
  • AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.

Amazon Web Services has rolled out Amazon Bio Discovery, a no-code AI tool that speeds up early-stage drug research. Scientists pick from a library of biological foundation models to generate and score new molecules. An onboard AI agent guides model selection, parameter settings and result interpretation. Once candidates clear computational screening, they’re sent to lab partners—like Twist Bioscience in a Memorial Sloan Kettering collaboration—where nearly 300,000 AI-designed antibodies were winnowed down to 100,000 for physical testing, cutting months of work into weeks. Big names have already signed on. Bayer, the Broad Institute and Voyager Therapeutics are among early adopters. In fact, 19 of the top 20 global pharma firms already use AWS cloud services. Rajiv Chopra, AWS’s vice president for healthcare AI, says the main bottleneck today is translating lab questions into machine-learning pipelines. The service is meant to assist scientists and contract research organizations, not replace them. Outside drug design, AWS, Boston Consulting Group and Merck are teaming up on another AI platform to improve clinical trial site selection, a frequent hold-up in taking new drugs from lab to market. Jefferies analyst Tycho Peterson notes that fears of AI cutting demand for research instruments are overblown; higher R&D returns could spur more spending on these tools.

Ask about this article